Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$9.71 ▼ -0.04
(-0.46%)
MKT CAP: $932.1M • VOL: 499.2K
52W L $7 52W H $15
MGTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $81.4M | $33.3M | $14.0M |
| YoY Revenue Growth % | +144.6% | +137.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$106.0M | -$164.2M | -$137.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | $0 | $0 | $0 |
| EBITDA (Normalized) | -$102.9M | -$160.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$46.4M | -$104.5M | -$105.4M |
| Capital Expenditures (CapEx) | $3.8M | $5.0M | — |
| Free Cash Flow (FCF) | -$50.2M | -$109.5M | -$105.4M |
| FCF Margin % | -61.7% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $65.9M | $103.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$5.8M | $67.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MGTX.